Disseminated intravascular coagulation – new pathophysiological concepts and impact on management

Expert Review of Hematology

Volumn 9, Issue 8, 2016, Pages 803-814

  Thachil, Jecko ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

anticoagulation; coagulation; disseminated intravascular coagulation; histones; Platelets

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; CYTOKINE; HEPARIN; PROTEIN C; PROTEIN S; THROMBOMODULIN; THROMBOPLASTIN; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; COMPLEMENT;

BLOOD TRANSFUSION; COMPLEMENT SYSTEM; DISSEMINATED INTRAVASCULAR CLOTTING; ERYTHROCYTE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LEUKOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASCULAR ENDOTHELIUM; BLOOD CELL; BLOOD CLOTTING; BLOOD CLOTTING TEST; COMORBIDITY; DISEASE MANAGEMENT; DISEASE PREDISPOSITION; DISSEMINATED INTRAVASCULAR COAGULATION; IMMUNOLOGY; METABOLISM;

ANTICOAGULANTS; BIOMARKERS; BLOOD CELLS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; COMORBIDITY; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; DISEASE MANAGEMENT; DISEASE SUSCEPTIBILITY; DISSEMINATED INTRAVASCULAR COAGULATION; ENDOTHELIUM, VASCULAR; HUMANS;

EID: 84982953359     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1080/17474086.2016.1203250     Document Type: Review

References (106)

1. J.A.Spero, J.H.Lewis, U.Hasiba Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haesmost. 1980;43:28–33.
2. F.B.TaylorJr., C.H.Toh, W.K.Hoots, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–1330.•• This article brought in the concept of the ISTH definition of DIC.
3. M.Levi, C.H.Toh, J.Thachil, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British committee for standards in haematology. Br J Haematol. 2009 Apr;145(1):24–33.
4. H.ten Cate, S.H.Schoenmakers, R.Franco, et al. Microvascular coagulopathy and disseminated intravascular coagulation. Crit Care Med. 2001;29(7 Suppl):S95–S97.
5. J.Thachil, A.Falanga, M.Levi, et al. Scientific and standardization committee of the international society on thrombosis and hemostasis. Management of cancer-associated disseminated intravascular coagulation:guidance from the SSC of the ISTH. J Thromb Haemost. 2015;13(4):671–675.• The current consideration of DIC of cancer.
6. O.Erez, S.A.Mastrolia, J.Thachil. Disseminated intravascular coagulation in pregnancy:insights in pathophysiology, diagnosis and management. Am J Obstet Gynecol. 2015;213(4):452–463.
7. B.Østerud, E.Bjørklid. Sources of tissue factor. Semin Thromb Hemost. 2006;32:11–23.
8. R.Pawlinski, N.Mackman. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res. 2010;125(Suppl 1):S70–S73.
9. S.Gando, S.Nanzaki, S.Sasaki, et al. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost. 1998;79:1111–1115.
10. M.Levi. Management of cancer-associated disseminated intravascular coagulation. Thromb Res. 2016;140(Suppl 1):S66–S70.
11. J.-G.Wang, D.Manly, D.Kirchhofer, et al. Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice. J Thromb Haemost. 2009;7:1092–1098.
12. N.S.Key, N.Mackman. Tissue factor and its measurement in whole blood, plasma, and microparticles. Semin Thromb Hemost. 2010 Nov;36(8):865–867.
13. S.Nomura, M.Shimizu. Clinical significance of procoagulant microparticles. J Intensive Care. 2015 Jan 7;3(1):2.
14. P.M.Sandset, B.J.Warn-Cramer, V.M.L.Rao, et al. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor:evidence supporting a physiological role of EPI as a natural anticoagulant. Proc Natl Acad Sci U S A. 1991;88:708–712.
15. H.Tang, L.Ivanciu, N.Popescu, et al. Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol. 2007;171:1066–1077.
16. E.de Jonge, P.E.Dekkers, A.A.Creasey, et al. Tissue factor pathway inhibitor (TFPI) dose dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000;95:1124–1129.
17. C.T.Esmon. Protein C anticoagulant system–anti-inflammatory effects. Semin Immunopathol. 2012 Jan;34(1):127–3.
18. M.Levi. Activated protein C in sepsis:a critical review. Curr Opin Hematol. 2008 Sep;15(5):481–486.
19. M.Levi, J.Dörffler-Melly, P.Reitsma, et al. Aggravation of endotoxin induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood. 2003;101:4823–4827.
20. S.N.Faust, M.Levin, O.B.Harrison, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001;345:408–416.
21. K.Brohi, M.J.Cohen, M.T.Ganter, et al. Acute traumatic coagulopathy:initiated by hypoperfusion:modulated through the protein C pathway? Ann Surg. 2007;245:812–818.
22. Y.Yanagida, S.Gando, A.Sawamura, et al. Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma:comparison with acute coagulopathy of trauma-shock. Surgery. 2013;154(1):48–57.
23. K.Brohi, M.J.Cohen, M.T.Ganter, et al. Acute coagulopathy of trauma:hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma. 2008;64:1211–1217.
24. S.Gando, H.Wada, J.Thachil. Scientific standardization committee on DIC ISTH:differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS). J Thromb Haemost. 2013;11:826–835.• This review discusses the confusion among trauma specialists about DIC.
25. J.H.Levy, R.M.Sniecinski, I.J.Welsby, et al. Antithrombin:anti-inflammatory properties and clinical applications. Thromb Haemost. 2016 Apr 1;115(4):712–728.
26. S.M.Opal. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med. 2000;28:S34–S37.
27. M.C.Minnema, A.C.Chang, P.M.Jansen, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood. 2000;95:1117–1123.
28. J.M.Leitner, C.Firbas, F.B.Mayr, et al. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin Pharmacol Ther. 2006;79:23–34.
29. L.Ostrovsky, R.C.Woodman, D.Payne, et al. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation. 1997;96:2302–2310.
30. D.C.Rijken, H.R.Lijnen. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost. 2009;7(1):4–13.
31. G.Pralong, T.Calandra, M.P.Glauser, et al. Plasminogen activator inhibitor 1:a new prognostic marker in septic shock. Thromb Haemost. 1989;61(3):459–462.
32. R.M.Mesters, N.Flörke, H.Ostermann, et al. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost. 1996;75(6):902–907.
33. S.Madoiwa, S.Nunomiya, T.Ono, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006;84(5):398–405 37.
34. M.Hayakawa, A.Sawamura, S.Gando, et al. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis. Thromb Res. 2012;130(6):906–913.
35. S.Zeerleder, V.Schroeder, C.E.Hack, et al. TAFI and PAI-1 levels in human sepsis. Thromb Res. 2006;118(2):205–212.
36. M.Emonts, E.L.E.de Bruijne, A.H.C.Guimarães, et al. Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost. 2008;6(2):268–276.
37. I.Raza, R.Davenport, C.Rourke, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013;11:307–314.
38. B.A.Cotton, J.A.Harvin, V.Kostousouv, et al. Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg. 2012;73:365–370.
39. J.C.Cardenas, N.Matijevic, L.A.Baer, et al. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients. Shock. 2014;41:514–521.
40. K.Abeyama, D.M.Stern, Y.Ito, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest. 2005;115:1267–1274.
41. M.Nesheim, W.Wang, M.Boffa, et al. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost. 1997 Jul;78(1):386–391.
42. H.Wang, I.Vinnikov, K.Shahzad, et al. The lectin-like domain of thrombomodulin ameliorates diabetic glomerulopathy via complement inhibition. Thromb Haemost. 2012;108:1141–1153.
43. M.Nakahara, T.Ito, K.Kawahara, et al. Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism. PLoS One. 2013;8:e7596.
44. T.Ito, I.Maruyama. Thrombomodulin:protectorate god of the vasculature in thrombosis and inflammation. J Thromb Haemost. 2011 Jul;9(Suppl 1):168–7.
45. S.Reitsma, D.W.Slaaf, H.Vink, et al. The endothelial glycocalyx:composition, functions, and visualization. Pflugers Archiv Eur J Physiol. 2007;454:345–359.
46. C.Chelazzi, G.Villa, P.Mancinelli, et al. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit Care. 2015 Jan 28;19:26.
47. D.Chappell, M.Jacob, K.Hofmann-Kiefer, et al. Antithrombin reduces shedding of the endothelial glycocalyx following ischaemia/reperfusion. Cardiovasc Res. 2009 Jul 15;83(2):388–396.
48. X.Marechal, R.Favory, O.Joulin, et al. Endothelial glycocalyx damage during endotoxemia coincides with microcirculatory dysfunction and vascular oxidative stress. Shock. 2008;29:572–576.
49. M.Nieuwdorp, M.C.Meuwese, H.L.Mooij, et al. Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. Atherosclerosis. 2009;202:296–303.
50. S.R.Ostrowski, P.I.Johansson. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. J Trauma Acute Care Surg. 2012;73:60–66.
51. P.I.Johansson, J.Stensballe, L.S.Rasmussen, et al. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011;254:194–200.
52. P.C.Liaw, T.Ito, T.Iba, et al. DAMP and DIC:the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood Rev. 2015 Dec 31. [Epub ahead of print].
53. J.Xu, X.Zhang, R.Pelayo, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009 Nov;15(11):1318–1321.• This paper brought into the light the idea of histones to the forefront.
54. J.-E.Kim, N.Lee, J.-Y.Gu, et al. Circulating levels of DNA-histone complex and dsDNA are independent prognostic factors of disseminated intravascular coagulation. Thromb Res. 2015 Jun;135(6):1064–1069.
55. S.T.Abrams, N.Zhang, J.Manson, et al. Circulating histones are mediators of trauma-associated lung injury. Am J Respir Crit Care Med. 2013;187:160–169.
56. M.Nakahara, T.Ito, K.I.Kawahara, et al. Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism. PLoS One. 2013;8:e75961.
57. C.Kannemeier, A.Shibamiya, F.Nakazawa, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A. 2007;104:6388–6393.
58. D.J.Dwivedi, L.J.Toltl, L.L.Swystun, et al. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Crit Care. 2012;16:R151.
59. C.Longstaff, I.Varjú, P.Sótonyi, et al. Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones. J Biol Chem. 2013 Mar 8;288(10):6946–6956.
60. K.Okajima. The role of leukocytes in disseminated intravascular coagulation associated with sepsis. Sepsis. 1999;3:135–142.
61. B.A.Bouchard, P.B.Tracy. The participation of leukocytes in coagulant reactions. J Thromb Haemost. 2003 Mar;1(3):464–469.
62. V.Brinkmann, A.Zychlinsky. Beneficial suicide:why neutrophils die to make NETs. Nat Rev Microbiol. 2007 Aug;5(8):577–582.
63. K.Martinod, D.D.Wagner. Thrombosis:tangled up in NETs. Blood. 2014;123(18):2768–2776.
64. T.A.Fuchs, A.Brill, D.Duerschmied, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107:15880–15885.• This paper linked extracellular DNA to thrombosis.
65. S.R.Clark, A.C.Ma, S.A.Tavener, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007;13:463–469.
66. T.J.Gould, T.T.Vu, L.L.Swystun, et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1977–1984.
67. M.F.Whelihan, K.G.Mann. The role of the red cell membrane in thrombin generation. Thromb Res. 2013 May;131(5):377–382.
68. A.Hill, R.J.Kelly, P.Hillmen. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985–4996.
69. M.Y.Lim, K.I.Ataga, N.S.Key. Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol. 2013 Sep;20(5):472–477.
70. H.B.Moore, E.E.Moore, E.Gonzalez, et al. Hemolysis exacerbates hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis:evolving concepts of the spectrum of fibrinolysis in response to severe injury. Shock. 2015;43:39–46.
71. T.van der Poll, E.de Jonge, M.Levi. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost. 2001;27:639–651.
72. M.T.Lotze, K.J.Tracey. High-mobility group box 1 protein (HMGB1):nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–342.
73. U.Andersson, K.J.Tracey. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139–162.
74. T.Ito, K.Kawahara, T.Nakamura, et al. High mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost. 2007;5:109–116.
75. T.Hatada, H.Wada, T.Nobori, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost. 2005;94:975–979.
76. J.H.Morrissey, S.A.Smith. Polyphosphate as modulator of hemostasis, thrombosis, and inflammation. J Thromb Haemost. 2015;13(Suppl 1):S92–S97.
77. J.M.Wat, J.H.Foley, M.J.Krisinger, et al. Polyphosphate suppresses complement via the terminal pathway. Blood. 2014 Jan 30;123(5):768–776.
78. E.M.Conway. Reincarnation of ancient links between coagulation and complement. J Thromb Haemost. 2015;13(Suppl. 1):S121–S32.
79. K.Ritis, M.Doumas, D.Mastellos, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177:4794–4802.
80. F.Lupu, R.S.Keshari, J.D.Lambris, et al. Crosstalk between the coagulation and complement systems in sepsis. Thromb Res. 2014 May;133(Suppl 1):S28–S31.
81. T.J.Gould, Z.Lysov, P.C.Liaw. Extracellular DNA and histones:double-edged swords in immunothrombosis. J Thromb Haemost. 2015 Jun;13(Suppl 1):S82–S91.
82. S.Gando, Y.Otomo. Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. Crit Care. 2015 Feb 23;19:72.• A wonderful summary of immunothrombosis.
83. H.Wada, J.Thachil, M.Di Nisio, et al. The scientific standardization committee on DIC of the international society on thrombosis haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11:761–767. doi:10.1111/jth.12155•• The harmonised guidance is the standard for the management of DIC.
84. T.Iba, T.Ito, I.Maruyama, et al. Potential diagnostic markers for disseminated intravascular coagulation of sepsis. Blood Rev. 2016 Mar;30(2):149–155.
85. K.Bakhtiari, J.C.Meijers, E.de Jonge, et al. Prospective validation of the international society of thrombosis and haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med. 2004 Dec;32(12):2416–2421.
86. H.Wada, E.C.Gabazza, H.Asakura, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC):diagnostic criteria of the international society of thrombosis and hemostasis and of the Japanese ministry of health and welfare for overt DIC. Am J Hematol. 2003 Sep;74(1):17–22.
87. T.Kaneko, H.Wada. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. J Clin Exp Hematop. 2011;51(2):67–76.
88. O.Grottke, T.Braunschweig, H.M.Spronk, et al. Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood. 2011 Aug 18;118(7):1943–1951.
89. X.-L.Liu, X.-Z.Wang, X.-X.Liu, et al. Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis:a prospective clinical study. Exp Ther Med. 2014 Mar;7(3):604–608.
90. N.Sakuragawa, H.Hasegawa, M.Maki, et al. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)–a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res. 1993 Dec 15;72(6):475–500.
91. G.R.Bernard, J.-L.Vincent, P.-F.Laterre, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709.
92. J.-F.Dhainaut, S.B.Yan, D.E.Joyce, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2:1924–1933.
93. V.M.Ranieri, B.T.Thompson, P.S.Barie, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055–2064.
94. A.C.Kalil, S.P.LaRosa. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis:a meta-analysis and metaregression. Lancet Infect Dis. 2012;12:678–686.
95. T.Iba, J.Thachil. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation:a perspective from Japan. Int J Hematol. 2016 Mar;103(3):253–261.
96. B.L.Warren, A.Eid, P.Singer, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis:a randomized controlled trial. JAMA. 2001;286:1869–1878.
97. T.Iba, A.Kidokoro. High dose antithrombin therapy for sepsis:mechanism of action. Shock. 2002;18:389–394.
98. T.Iba, D.Saitoh. Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation. J Intensive Care. 2014;2:66.
99. S.Gando, D.Saitoh, H.Ishikura, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013;17:R297.
100. T.Iba, D.Saitoh, S.Gando, et al. The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res. 2015;135:897–901.
101. H.Saito, I.Maruyama, S.Shimazaki, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation:results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.• The pivotal trial of thrombomodulin.
102. T.Tagami, H.Matsui, H.Horiguchi, et al. Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation:an observational nationwide study. J Thromb Haemost. 2015;13:31–40.
103. T.Tagami, H.Matsui, K.Fushimi, et al. Use of recombinant human soluble thrombomodulin in patients with sepsisinduced disseminated intravascular coagulation after intestinal perforation. Font Med. 2015;2:1–7.
104. K.Yamakawa, M.Aihara, H.Ogura, et al. Recombinant human soluble thrombomodulin in severe sepsis:a systematic review and meta-analysis. J Thromb Haemost. 2015;13:508–519.
105. J.L.Vincent, M.K.Ramesh, D.Ernest, et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41:2069–2079.
106. M.Di Nisio, J.Thachil, A.Squizzato. Management of disseminated intravascular coagulation:a survey of the international society on thrombosis and haemostasis. Thromb Res. 2015 Aug;136(2):239–242.